Anchoring aspirin onto cisplatin could create a cancer treatment capable of overcoming drug resistance in cisplatin resistant cells, new research shows.
Cisplatin, along with other chemotherapeutic drugs, is used to treat various types of cancer, including testicular, ovarian, lung and bladder cancer. However, clinical use of cisplatin is limited by developing resistance, earning it the nickname the ‘penicillin of cancer’. Resistance mechanisms to cisplatin are well defined, but there are still no treatments available to surmount or reverse it.
Upon cellular uptake, asplatin is reduced by ascorbic acid to give cisplatin and aspirin
Read the full article in Chemistry World»
Read the original journal article in ChemComm – it’s free to access until 22nd April:
The Ligation of Aspirin to Cisplatin Demonstrates Significantly Synergistic Effect to Tumor Cells
Qinqin Cheng, Hongdong Shi, Hong-Xia Wang, Yuanzeng Min, Jun Wang and Yangzhong Liu
Chem. Commun., 2014, Accepted Manuscript, DOI: 10.1039/C4CC00419A
